siponimod
| SMILES | CCc1cc(ccc1CN1CC(C1)C(=O)O)/C(=N/OCc1ccc(c(c1)C(F)(F)F)C1CCCCC1)/C |
| InChIKey | KIHYPELVXPAIDH-HNSNBQBZSA-N |
Chemical properties
| Hydrogen bond acceptors | 4 |
| Hydrogen bond donors | 1 |
| Rotatable bonds | 9 |
| Molecular weight (Da) | 516.3 |
Drug properties
| Molecular type | Small molecule |
| Physiological/Surrogate | Surrogate |
| Approved drug | Yes |
Bioactivities
| Receptor | Activity | Source | |||||||
|---|---|---|---|---|---|---|---|---|---|
| GTP | Uniprot | Species | Family | Class | Type | Min | Avg | Max | Database |
| Receptor | Activity | Source | |||||||
|---|---|---|---|---|---|---|---|---|---|
| GTP | Uniprot | Species | Family | Class | Type | Min | Avg | Max | Database |
| S1P1 | S1PR1 | Human | Lysophospholipid (S1P) | A | pEC50 | 9.754999999999999 | 9.75 | 9.75 | Guide to Pharmacology |
| S1P3 | S1PR3 | Human | Lysophospholipid (S1P) | A | pEC50 | 5.3 | 5.3 | 5.3 | Guide to Pharmacology |
| S1P4 | S1PR4 | Human | Lysophospholipid (S1P) | A | pEC50 | 6.12 | 6.12 | 6.12 | Guide to Pharmacology |
| S1P5 | S1PR5 | Human | Lysophospholipid (S1P) | A | pEC50 | 9.01 | 9.01 | 9.01 | Guide to Pharmacology |
| S1P5 | S1PR5 | Human | Lysophospholipid (S1P) | A | pEC50 | 9.01 | 9.01 | 9.01 | ChEMBL |
| S1P4 | S1PR4 | Human | Lysophospholipid (S1P) | A | pEC50 | 6.12 | 6.12 | 6.12 | ChEMBL |
| S1P1 | S1PR1 | Human | Lysophospholipid (S1P) | A | pEC50 | 8.03 | 8.03 | 8.03 | Drug Central |
| S1P2 | S1PR2 | Human | Lysophospholipid (S1P) | A | pEC50 | 8.4 | 8.4 | 8.4 | Drug Central |
| S1P3 | S1PR3 | Human | Lysophospholipid (S1P) | A | pEC50 | 8.52 | 8.52 | 8.52 | Drug Central |
| S1P4 | S1PR4 | Human | Lysophospholipid (S1P) | A | pEC50 | 8.21 | 8.21 | 8.21 | Drug Central |
| S1P5 | S1PR5 | Human | Lysophospholipid (S1P) | A | pEC50 | 8.05 | 8.05 | 8.05 | Drug Central |
| S1P1 | S1PR1 | Human | Lysophospholipid (S1P) | A | pEC50 | 9.4 | 9.4 | 9.4 | ChEMBL |
| S1P3 | S1PR3 | Human | Lysophospholipid (S1P) | A | pEC50 | 5.3 | 5.3 | 5.3 | ChEMBL |